Get In Touch

Cancer is characterized by abnormal uncontrolled proliferation of cells caused due to mutations which result in tumor formation migrating to different parts of the human body. This migration of tumor cells is termed metastasis. Cancer supportive care therapeutics comprise drugs used to prevent and treat cancer. These reduce side effects caused because of cancer treatments, thereby assisting in increasing the life expectancy of individuals. These cancer supportive care therapeutics are used to treat pain due to cancer, neutropenia, nausea caused due to chemotherapy, and bone metastasis. According to the American Society of Cancer, the total number of individuals diagnosed with cancer in the U.S. is estimated to be 15.5 million.

Cancer supportive care therapeutics is an emerging trend in cancer treatment as it significantly due to rapid increases drug discovery and development process for therapeutics which are able to decrease the after-effects of complication arising during and after cancer treatment in an individual thus assisting in increasing the life expectancy of cancer patients. Increasing awareness and collaboration by leading organizations to promote cancer supportive care programs is expected to drive the market during the forecast period. For instance, in 2007, the National Palliative Care Research Center and the American Cancer Society invested in palliative care and symptom management to improve the quality of life of cancer patients and survivors. The collaboration also aimed at increasing research activity in cancer palliative care.

The European Society for Medical Oncology has proposed a set of clinical guidelines which are a set of recommendations for cancer care. These guideline address the management of anticancer therapy, febrile neutropenia, prevention of chemotherapy and radiotherapy-induced nausea and vomiting, treatment of dyspnea in advance cancer stages, oral and gastrointestinal mucosal injury, advanced care planning in palliative care, bone health, and other cancer supportive care. The global cancer supportive care therapeutics market has been segmented based on drug type, indication type, distribution channel, and region. In terms of drug type, the market has been segmented into allopurinol, rasburicase, amifostine, colony-stimulating factors, and others. Based on indication type, the market has been classified into cancer pain, chemotherapy-induced anemia, chemotherapy induced neutropenia, chemotherapy-induced nausea & vomiting, oral mucositis, and bone metastasis. In terms of distribution channel, the cancer supportive care therapeutics market has been classified into hospital pharmacies, retail pharmacies, and e-commerce.

Major drivers of the cancer supportive care therapeutics market are increasing prevalence of cancer disease, rapidly developing biopharmaceutical industry, rising academic & clinical research activity, increasing collaboration between organizations to spread awareness, changing lifestyle, advancements in the health care industry, launch of novel therapeutics, and increasing per capita income in emerging markets. Increasing growth in the biopharmaceutical industry has resulted in major advancement in cancer research and treatment. Developments in drug discovery have resulted in decreased mortality rates among cancer patients. There have been major improvements in cancer pain management; however, these improvements have been underutilized due to poor assessment by physicians and lack of adequate knowledge of newer drugs and treatment. Lack of awareness about different therapeutics used during cancer supportive care in emerging economies, high cost of treatment, rigid government regulation, and unfavorable reimbursement rates are the major restraints of the cancer supportive care therapeutics market.

Geographically, the global cancer supportive care therapeutics market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the cancer supportive care therapeutic market due of increasing population, rising patient pool, growing geriatric population, increasing number of screening procedures, presence of leading manufacturers, and technological advancements. North America is closely followed by Europe and Asia Pacific. Asia Pacific is an emerging market for cancer supportive care therapeutics primarily because of increasing health care expenditure in the region, rising population, and growing awareness.

Key players in the global spasticity treatment market are Amgen, Inc., Bayer AG, Daiichi Sankyo Company Limited, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Depomed, Inc., Eli Lilly and Company, and Merck & Co., Inc., among others.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Cancer Supportive Care Therapeutics Market

Pre Book